research A Comparison of Varying alpha-Blockers and Other Pharmacotherapy Options for Lower Urinary Tract Symptoms.
Alpha-blockers are the most effective and widely used treatment for lower urinary tract symptoms, with minimal side effects.
Search
for
Sort by
Research
30 / 1000+ results
research Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial
Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.
research Immunologic adverse reactions of β-blockers and the skin (Review)
β-blockers can cause skin problems like psoriasis and vitiligo, and doctors should tell patients about these risks.
research CUTANEOUS SIDE-EFFECTS OF BETA-ADRENERGIC BLOCKERS
Beta-blockers can cause rare skin side-effects, which usually improve after stopping the medication.
research Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs
α-Blockers and 5-ARIs for BPH can cause sexual dysfunction, including erectile and ejaculatory issues.
research Impact of Alpha Blockers, 5-alpha Reductase Inhibitors and Combination Therapy on Sexual Function
Medications for enlarged prostate can cause sexual side effects like reduced libido, erectile dysfunction, and ejaculatory problems.
research COMPARISON OF FINASTERIDE AND ALPHA‐BLOCKERS AS INDEPENDENT RISK FACTORS FOR ERECTILE DYSFUNCTION
Age and other health issues affect erectile dysfunction more than finasteride or alpha-blockers.
research Comparison of Different Alpha-blocker Combinations in Male Hypertensives with Refractory Lower Urinary Tract Symptoms
The doxazosin plus tamsulosin combination improved symptoms effectively with fewer side effects.
research Alopecia and drug eruption of the scalp associated with a new beta-blocker, nadolol.
Stopping the beta-blocker nadolol led to quick hair regrowth and improved scalp condition.
research A retrospective study of clinical outcomes of α-blocker or finasteride monotherapy followed by combination therapy: determination of the period of combination therapy of α-blocker and finasteride
Combination therapy for 9+ months maintains symptom improvements after stopping alpha-blockers or finasteride.
research Effect of dose reduction of dutasteride in combination with alpha-blockers in patients with lower urinary tract symptoms/benign prostatic enlargement
Taking dutasteride every other day works as well as daily and better preserves sexual function.
research IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the IsoPSA Validation Study
IsoPSA test works accurately even if patients take certain prostate medications.
research Intraoperative Iris Behavior during Phacoemulsification Maneuvers in Rabbits Treated with Selective α1-Blocker, 5α-Reductase Inhibitor, or Anxiolytic Medication
Tamsulosin increases the risk of floppy iris during eye surgery.
research Alpha Blocker and 5-Alpha Reductase Inhibitor Prescribing Habits among Urologists and Primary Care Physicians
Urologists prescribe newer medications more often than primary care physicians, who could benefit from more education on treatment options.
research Do Alpha-Blockers and 5-Alpha Reductase Inhibitors Increase Dementia Risk? A Network Meta-analysis
Alpha-blockers and 5-alpha reductase inhibitors don't significantly increase dementia risk.
research A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment
TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.
research Alpha Blockers and Finasteride for BPH-1996
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Ciclosporin-Induced Generalised Hypertrichosis in a Transgender Woman Receiving Testosterone Blockers
Ciclosporin can cause excessive hair growth even with testosterone blockers.
research Calcium blockers protect against sensory epithelial damage and hearing loss in Cx26-cKO mice
Calcium blockers may help prevent hearing loss by protecting hair cells.
research Review: Adding α1-blockers to 5α-reductase inhibitors improves lower urinary tract symptoms in men
Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
research Alpha-blockers/finasteride: no benefit in ED
research Alopecia areata as another immune‐mediated disease developed in patients treated with tumour necrosis factor‐α blocker agents
Anti-TNF-α therapy may increase the risk of developing alopecia areata, especially in those with a history of autoimmune disease.
research Influence of the alkylsulfonylamino substituent located at the 6-position of 2,2-dimethylchromans structurally related to cromakalim: From potassium channel openers to calcium entry blockers?
New compounds similar to cromakalim were less effective at inhibiting insulin release but improved in solubility and one acted as a calcium entry blocker, not a potassium channel opener.
research Generalized hypertrichosis associated with the use of interleukin 17 blockers in 2 patients with psoriasis
Two patients with psoriasis grew extra hair after using certain psoriasis medications.
research EFFECTS OF FESOTERODINE, A NOVEL ANTIMUSCARINIC, ALONE AND IN COMBINATION WITH AN α-RECEPTOR BLOCKER, DOXAZOSIN, ON BLADDER FUNCTION IN OBSTRUCTED RATS
Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.
research Dose-dependent and long term effects of RU58841 (androgen receptor blocker) on hair growth in the bald stumptailed Macaque.
RU58841, an androgen receptor blocker, significantly increased hair density, thickness, and length in monkeys when applied topically daily for several months.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
research Bullous Congenital Ichthyosiform Erythroderma with Tinea Capitis in Half-Siblings: Rare Phenomenon in Ichthyosis with Co-Existing Trichophyton rubrum Infection and Blocker Displacement Amplification for Mosaic Mutation Detection
Half-siblings with a rare skin condition improved with treatment for a fungal infection, but hair loss remained.